Traded Aug 13 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Traded Jul 16, 2026 · Filed Jul 17, 2026
United Therapeutics's & GENERAL COUNSEL sold $813K of United Therapeutics shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$812,648
Shares × reported transaction price
71 days after results of May 6, 2026, 20 days before results of Aug 5, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −1.3% | −0.6% | −0.8% |
| 30 days | −5.1% | +4.0% | −9.0% |
Past results only. Not a forecast.
Traded Aug 13 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Martine A Rothblatt (Chairperson & CEO) sold ~$627K of United Therapeutics
Scheduled in advanceMartine A Rothblatt (Chairperson & CEO) sold ~$665K of United Therapeutics
Scheduled in advance